Efficacy and safety of change the antiplatelet agent in patients with chronic noncardioembolic ischemic stroke - multi-center prospective study -

Efficacy and safety of change the antiplatelet agent in patients with chronic noncardioembolic ischemic stroke - multi-center prospective study - - Efficacy and safety of change the antiplatelet agent in patients with chronic noncardioembolic ischemic stroke

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004611

Enrollment

120

Registered

2010-12-01

Start date

2010-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

noncardioembolic ischemic stroke

Interventions

Treatment with cilostazol group(100mg-200mg/day)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with noncardioembolic ischemic stroke. 2. Patients with stroke of Primary or recurrent. 3. Patient's Symptoms of stroke is stable when obtaining consent 4. Patients who agreed to participate with the written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with cardioembolic ischemic stroke. 2. Patients with hemorrhage or bleeding tendency. 3. Patients with congestive heart failure. 4. Patients with a history of hypersensitivity to ingredients of cilostazol. 5. Pregnant, possibly pregnant, or nursing women. 6. Patients on cilostazol 7. Patients with CAS for asymptomatic stroke. 8. Patients during the argatroban, ozagrel sodium or scheduled. 9. Patients during the rt-PA or scheduled. 10. Patients with scheduled on neuroendovascular therapy. 11. Patients on experimental drug or scheduled. 12. Patients who are otherwise judged inappropriate for inclusion in the study by the investigators.

Design outcomes

Primary

Measure	Time frame
Episode of headache, palpitation, tachycardia.	—

Secondary

Measure	Time frame
1. Withdrawal for adverse effect. (headache, palpitation, tachycardia) 2. Episode of adverse effect to exclusion of headache, palpitation, tachycardia. 3.Change of mRS.	—

Countries

Japan

Contacts

Public ContactMasaaki Uno

Kawasaki Medical School Hospital Neurosurgery

muno@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026